Innoviva, Inc. balance sheet INVA

Annual Quarterly

As of Sep 30, 2026, Innoviva, Inc. had total assets of $1.5 billion. Total assets were up 7.6% from a year earlier. Stockholders' equity was $1.1 billion. It held $986.2 million in cash and investments against $269.9 million of total debt, net cash of $716.4 million. The current ratio, current assets divided by current liabilities, was 15.44.

USD in millions, except ratios and per-share amounts. The percent under a figure is the change from the year before.

Line	FY 2026 Sep 30, 2026	FY 2025 Dec 31, 2025	FY 2024 Dec 31, 2024	FY 2023 Dec 31, 2023	FY 2022 Dec 31, 2022	FY 2021 Dec 31, 2021	FY 2020 Dec 31, 2020	FY 2019 Dec 31, 2019	FY 2018 Dec 31, 2018	FY 2017 Dec 31, 2017	FY 2016 Dec 31, 2016
Assets
Cash	581 +22.0%	551 +80.7%	305 +57.6%	194 -33.5%	291 +44.4%	202 -18.2%	246 -11.4%	278 +345.5%	62 -14.9%	73 -37.9%	118 -25.9%
Short-term investments	—	—	—	—	—	—	0 -100.0%	73 +38.6%	52 -5.8%	56 +71.9%	32 +15.4%
Long-term investments	405 +17.8%	404 +18.4%	342 -23.1%	444 +22.1%	364 -24.8%	484 +10.4%	438	—	—	—	—
Cash and investments	986 +20.2%	955 +47.8%	647 +1.4%	638 -2.6%	655 -4.4%	685 +0.1%	685 +95.2%	351 +205.3%	115 -11.0%	129 -14.2%	150 -19.7%
Inventory	43 +11.7%	39 +16.2%	34 -17.2%	41 -27.1%	56	—	—	—	—	—	—
Total current assets	772 +12.8%	728 +31.2%	554 +61.0%	344 -22.4%	444 +41.4%	314 -8.3%	342 -20.7%	431 +116.7%	199 -0.7%	200 +1.2%	198 -7.6%
Property and equipment, net	2 +33.3%	2 +202.5%	1 +6.4%	0 +184.1%	0 +1316.7%	0 -57.1%	0 -15.2%	0 -79.4%	0 -23.4%	0 -43.2%	0 +66.5%
Goodwill	18 +0.0%	18 +0.0%	18 +0.0%	18 -33.0%	27	—	—	—	—	—	—
Total assets	1,538 +7.6%	1,635 +25.7%	1,301 +4.6%	1,244 +1.0%	1,231 +32.9%	926 -7.3%	1,000 +37.9%	725 +32.2%	548 +49.2%	367 -3.1%	379 -7.3%
Liabilities and equity
Accounts payable	6 +4.1%	5 +132.9%	2 -68.3%	7 +128.5%	3 +10785.2%	0 -59.1%	0 +560.0%	0 -9.1%	0 -98.2%	1 +369.5%	0 -84.4%
Total current liabilities	50 +3.2%	50 -78.9%	236 +519.1%	38 -71.7%	135 +2224.2%	6 -5.0%	6 +13.8%	5 -5.8%	6 -83.6%	35 +73.3%	20 +48.6%
Stockholders' equity	1,138	1,173	—	—	566 +36.4%	415 -23.2%	540 +72.2%	313 +104.1%	154 +163.2%	-243 +31.2%	-353 -3.0%
Debt
Debt due within a year	—	—	192	—	96	—	—	—	—	—	8 -99.0%
Long-term debt	259 +0.6%	258 +0.6%	256 -42.6%	446 +0.5%	444 +12.5%	395 +2.4%	386 +2.2%	377 -1.5%	383 -33.3%	574 -18.9%	708
Lease liabilities	11 +597.1%	11 +310.3%	3 -3.2%	3 -23.0%	4	—	—	—	—	—	—
Total debt	270 +4.2%	269 -40.4%	451 +0.4%	449 -17.5%	544 +37.9%	395 +2.4%	386 +2.2%	377 -1.5%	383 -33.3%	574 -19.8%	716 -4.3%
Net cash	716 +27.6%	686 +251.1%	196 +3.5%	189 +70.4%	111 -61.9%	291 -2.8%	299 +1238.8%	-26 +90.2%	-268 +39.8%	-445 +21.3%	-566 -0.8%
Ratios
Current ratio	15.44x	14.64x	2.35x	9.03x	3.29x	54.02x	55.98x	80.29x	34.92x	5.77x	9.88x
Debt to equity	0.24x	0.23x	—	—	0.96x	0.95x	0.71x	1.20x	2.49x	—	—
Debt to EBITDA	—	—	—	—	—	1.01x	1.15x	1.45x	1.52x	2.91x	5.82x
Return on equity	17.01%	23.12%	—	—	38.93%	88.93%	54.42%	60.92%	264.57%	—	—
Return on assets	12.58%	16.58%	1.80%	14.45%	17.89%	39.81%	29.39%	26.35%	74.12%	36.55%	—
Book value per share	15.90	15.71	—	—	8.18	5.96	5.32	3.10	1.52	—	—

How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except ratios and per-share amounts. Cash and investments adds short-term and long-term marketable securities to cash. Debt due within a year is the borrowings that are not already in long-term debt. Total debt is those borrowings plus lease liabilities. Net cash is cash and investments minus total debt. Return on equity and return on assets divide the trailing twelve months of net income by the balance on that date. Debt to EBITDA uses the trailing twelve months of EBITDA. The first column is the latest balance sheet when it is newer than the latest fiscal year. More on our methodology.

Company profile

Industry: Pharmaceutical Preparations (SIC 2834)
Listed as: INVA (Nasdaq)
Fiscal year ends: December 31
Incorporated in: DE
Headquarters: Burlingame, CA
SEC filer status: Large accelerated filer
SEC CIK: 1080014
Former names: THERAVANCE INC (until Dec 7, 2015); ADVANCED MEDICINE INC (until Aug 2, 2000)

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.